Human RCT
Mensch
Lumry WR, et al. 2011
In randomized trials (FAST), markedly shortens time to symptom relief in acute HAE attacks.
What does NOT follow: For acute treatment of the approved indication; no maintenance/prophylaxis claim.
Peptide entry · Research other
Icatibant
Firazyr · HOE-140
Highest evidence
Human RCT
Studies recorded
1· 1 in humans
Legal status · US
PrescriptionScientific context only. Not medical advice, not a recommendation to use.
At a glance
Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE).
Researched for
Hereditary angioedema (acute attack)Bradykinin-mediated swelling
Official status
US: Prescription
FDA-approved (2011, Firazyr) for acute treatment of HAE attacks.
At a glance
01
Mechanism of action
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Injection-site reactions (redness, swelling, pain)
Near-universal, usually mild and transient.
sehr häufig
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Human RCTRandomised controlled trial
Lumry WR, et al. · 2011
Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial
SamplePatients with hereditary angioedema (C1-inhibitor deficiency/dysfunction) during acute attacks.
EndpointTime to ≥50% reduction in symptom severity.
Concrete results
Time to symptom relief
2,0 vs 19,8 h
vs Placebo
Findings:Icatibant markedly shortened median time to symptom relief versus placebo (2.0 vs. 19.8 h).
Limitations:Acute endpoints; rare disease.
15
Sources & method
Last reviewed
2026-06-11
Get new studies on Icatibant
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy